/

Società

En

Non verificato

Enveda

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

18 comunicati stampa

Guarda tutti i comunicati

27/10/2026

Enveda Collaborates with Anthropic to Accelerate Drug Development

Fonte

Emittente

1.00

0

29/09/2026

Eventi

Industria

Scienza

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Enveda Announces Late-Breaker Oral Presentation of New Mechanistic and Biomarker Data from the Phase 1b Trial of ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, at the Upcoming EADV 2026 Congress

Fonte

Emittente

1.00

0

23/09/2026

Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century

Fonte

Emittente

1.00

0

15/09/2026

Tecnica

Scienza

Software

Biotecnologia

Salute

Farmaceutica

Sanità

Appalti e gare

Industria

Enveda Is Launching the Next AlphaFold Contest. This Time, to Solve the Structures of 90% of Biological Molecules That No One Can Identify.

Fonte

Emittente

1.00

0

18/08/2026

Multimedialità

Industria

Salute

Fitness

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Enveda Reports Positive Phase 1 Results for ENV-308, the First Pill Designed From the Chemistry of Exercise

Fonte

Emittente

1.00

0

23/07/2026

Multimedialità

Eventi

Industria

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy; Additional Details to Be Shared at EADV

Fonte

Emittente

1.00

0

15/04/2026

Mercato del lavoro

Salute

Tecnica

Scienza

Farmaceutica

Biotecnologia

Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations

Fonte

Emittente

1.00

0

31/03/2026

Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis

Fonte

Emittente

1.00

0

23/12/2025

Scienza

Tecnica

Igiene alimentare

Medicina - Varie

Biotecnologia

Farmaceutica

Salute

Industria

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

Fonte

Emittente

1.00

0

17/12/2025

Mercato del lavoro

Industria

Scienza

Tecnica

Igiene alimentare

Medicina - Varie

Biotecnologia

Farmaceutica

Salute

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0